中国药业2024，Vol.33Issue(14)：99-101,3.DOI:10.3969/j.issn.1006-4931.2024.14.024
复荣通脉胶囊联合利拉鲁肽治疗2型糖尿病临床观察
Clinical Observation of Furong Tongmai Capsules Combined with Liraglutide in the Treatment of Diabetes Mellitus Type 2
摘要
Abstract
Objective To investigate the effects of Furong Tongmai Capsules combined with liraglutide on the blood glucose-related indexes,carotid atherosclerotic plaque area and fibrinogen(Fib)level in patients with diabetes mellitus type 2(T2DM).Methods A total of 90 patients with T2DM admitted to the hospital from January 2021 to December 2022 were selected and divided into the observation group and the control group by the random number table method,with 45 cases in each group.The patients in the two groups were given subcutaneous injection of Liraglutide Injection,on this basis,the patients in the observation group were given Furong Tongmai Capsules.Both groups were treated continuously for three months.Results After treatment,the traditional Chinese medicine(TCM)syndrome score,fasting blood glucose(FBG),2-hour postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1C)and Fib levels in the two groups significantly decreased(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.05).After treatment,the carotid atherosclerotic plaque area in the two groups significantly decreased(P<0.05),and that in the observation group was significantly smaller than that in the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(8.89% vs.24.44%,P<0.05).Conclusion Furong Tongmai Capsules combined with liraglutide can effectively decrease the blood glucose-related index levels,improve TCM syndromes and blood coagulation function,and relieve the carotid atherosclerosis in patients with T2DM.关键词
复荣通脉胶囊/利拉鲁肽/2型糖尿病/颈动脉粥样硬化/血糖/纤维蛋白原/中医证候Key words
Furong Tongmai Capsules/liraglutide/diabetes mellitus type 2/carotid atherosclerosis/blood glucose/fibrinogen/TCM syndrome分类
医药卫生引用本文复制引用
马艳霞,田风胜,崔荣岗,刘燕,孟莹莹,王凤英..复荣通脉胶囊联合利拉鲁肽治疗2型糖尿病临床观察[J].中国药业,2024,33(14):99-101,3.基金项目
河北省中医药管理局科研计划项目[2022249]. （）
